TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01012739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg via the Concept1 dry-powder inhaler
Description: Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg via the Concept1 dry-powder inhaler
Description: Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg via the Concept1 dry-powder inhaler
Description: Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg via the Concept1 dry-powder inhaler
Description: Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 60 μg via the Simoon dry-powder inhaler
Description: Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 60 μg via the Simoon dry-powder inhaler
Description: Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 60 μg via the Simoon dry-powder inhaler
Description: Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 60 μg via the Simoon dry-powder inhaler
Description: Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 120 μg via the Simoon dry-powder inhaler
Description: Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 120 μg via the Simoon dry-powder inhaler
Description: Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 120 μg via the Simoon dry-powder inhaler
Description: Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 120 μg via the Simoon dry-powder inhaler
Description: Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
Study: NCT01639378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Symplicity Catheter System
Study: NCT01012739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol via the Concept1 dry-powder inhaler
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol via the Concept1 dry-powder inhaler
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol via the Concept1 dry-powder inhaler
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol via the Concept1 dry-powder inhaler
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
Study: NCT03401229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg SC + Mometasone Furoate
Description: Benralizumab injection is 30mg/ml SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Benralizumab 30 mg SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo SC + Mometasone Furoate
Description: Matching placebo injection is SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Matching placebo SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study.
Study: NCT02088437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Description: additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: once daily physiotherapy whilst acute hospital inpatient
Study: NCT03107104

Intervention type: DEVICE
Intervention: Topcon DRI OCT Triton (plus)
Description: The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes

Intervention type: DEVICE
Intervention: TRC-50DX retinal camera
Description: The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
Study: NCT01696110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: heparin monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: heparin monotherapy
Study: NCT04384185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Exercises:~* Pelvic tilt.~* brinding.~* cuadruped arm/leg raise.~* Abdominal strengthening exercises.~* Low-back muscles stretching.~* The side bridge.~* Side leg separation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Exercises:~* Pelvic tilt.~* brinding.~* cuadruped arm/leg raise.~* Abdominal strengthening exercises.~* Low-back muscles stretching.~* The side bridge.~* Side leg separation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: 1. Functional diaphragm balancing technique: gentle vertical pressure was applied for 5 minutes at the diaphragm level.~2. Muscle fiber stretching technique: a cranial traction was performed from the lower edge of the costal arches during the inspiratory breathing phase, for more than 10 respiratory cycles.~3. Phrenic-center inhibition technique (Figure 3C): the soft tissue was pumped during the expiratory phase by gently and simultaneously using both hands to create pressure in cranial and caudal direction, for more than 10 respiratory cycles.
Study: NCT04269330

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
Description: Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
Description: Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
Study: NCT00690820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase Delayed Release
Description: 12,000 unit Capsules, dosed individually based on fat intake.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study: NCT03832413

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).

Intervention type: DIAGNOSTIC_TEST
Intervention: DELPhI (TMS-EEG analysis)
Description: We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
Study: NCT00495287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytosine arabinoside
Description: Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytosine arabinoside
Description: Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin.
Study: NCT02661087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic resection with bipolar energy
Description: Hysteroscopic resection with bipolar energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic resection with monopolar energy
Description: Hysteroscopic resection with monopolar energy
Study: NCT03728556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1001 monoclonal antibody
Description: Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CS1001 placebo
Description: Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months
Study: NCT01696110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin plus tirofiban
Description: combined use of heparin and tirofiban during PCI
Study: NCT02896803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFLOX
Description: 5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
Study: NCT02201394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose
Description: Single loading dose of Ticagrelor 180 mg
Study: NCT01810120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR alfa beta T cell depletion
Description: total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
Study: NCT04822285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Triaging Intervention
Description: The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly\& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition\& follow up).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine psychological support
Description: For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
Study: NCT00063154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab was supplied as a single-use liquid formulation.
Study: NCT04685226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-723
Description: ICP-723 is a white, round, uncoated table
Study: NCT04235933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tai Ai(RC18) 80mg
Description: The patient received one treatment of RC18 80mg in the test group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tai Ai(RC18) 160mg
Description: The patient received one treatment of RC18 160mg in the test group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240mg
Description: The patient received one treatment of RC18 240mg in the test group
Study: NCT00121277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Study: NCT04384315

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
Study: NCT04011618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ellagic Acid / Pomegranate Extract
Description: Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
Study: NCT02201394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin loading dose
Description: Single loading dose of Aspirin 325 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor maintenance dose
Description: Ticagrelor 90 mg twice daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin maintenance dose
Description: Aspirin 81 mg once daily x 7 days
Study: NCT04489836

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutalytic®
Description: Glutalytic® capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DE111®
Description: DE111® capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal A
Description: Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal A
Description: Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
Study: NCT01660048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILS TEP repair
Description: perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total extraperitoneal inguinal hernia repair
Description: Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total extraperitoneal inguinal hernia repair
Description: Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
Study: NCT03162263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKso training
Description: Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKso training
Description: Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
Study: NCT02242526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietex™ Composite Hiatal Mesh, North Haven, CT
Description: Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
Study: NCT03794167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 50mg/kg/day i.v. on days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide 400mg/m2 day i.v. on days -5 and -4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: etoposide 400mg/m2 day i.v. on days -5 and -4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: melphalan 50mg/m2/day i.v. on days -3 and -2
Study: NCT02953171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw, lacto-fermented sauerkraut
Description: Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw, lacto-fermented sauerkraut
Description: Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mutaflor
Description: The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mutaflor
Description: The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pasteurized sauerkraut
Description: Sauerkraut without live bacteria.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurized sauerkraut
Description: Sauerkraut without live bacteria.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Capsules without probiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Capsules without probiotics
Study: NCT04211428

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT02782130

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Epic Allies App Intervention
Description: The Epic Allies app addresses barriers to ART adherence through:~1. Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.~2. Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.~3. A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.~4. Users progress through Epic Allies' virtual world, creating allies with other users.~5. The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Epic Allies - Control Branch
Description: Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
Study: NCT00681330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URC10, TTK, KOC1
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.